Skip to main content
. 2022 Sep 16;7(5):100586. doi: 10.1016/j.esmoop.2022.100586

Figure 2.

Figure 2

Forest plots of 5-year overall survival (OS) and 5-year disease-free survival (DFS) for the use versus no use of HIPEC in the treatment of primary ovarian cancer with interval cytoreduction following neoadjuvant chemotherapy (POC, interval CRS + NACT).

CI, confidence interval; HIPEC, hyperthermic intraperitoneal chemotherapy.